超镜夹在治疗消化性溃疡复发性出血方面比标准内镜治疗更有效
这项前瞻性随机试验在9个学术转诊中心纳入66例初始止血成功后复发性消化性溃疡出血的成人患者,比较超镜夹(OTSC)与标准治疗(经内镜夹或热疗加稀释肾上腺素注射)的疗效。主要终点为再出血(持续出血或7天内复发性出血的复合终点),OTSC组进一步出血发生率为15.2%,显著低于标准治疗组的57.6%(绝对差异42.4%,95%CI 21.6-63.2,P=.001)。结论认为OTSC内镜治疗优于标准治疗。
要点
- 复发性消化性溃疡出血患者中,OTSC组进一步出血发生率为15.2%,标准治疗组为57.6%,差异有统计学意义。
- 标准治疗组持续出血发生率为42.4%,OTSC组为6.0%,两组比较P=.001。
- 7天内复发性出血在标准治疗组为16.1%,OTSC组为9.1%,两组比较P=.468,无显著差异。
核心结论
- 在前瞻性随机试验中,对于复发性消化性溃疡出血患者,OTSC内镜治疗优于经内镜夹的标准治疗。
研究设计与样本
- 研究在德国、瑞士和香港的9个学术转诊中心进行,时间为2013年3月至2016年9月。
- 纳入初始止血成功后复发性消化性溃疡出血的成人患者,意向治疗分析共66例,按1:1随机分组接受OTSC或标准治疗。
- 标准治疗定义为经内镜夹(TTSC,n=31)或热疗加稀释肾上腺素注射(n=2)。
- 主要终点为进一步出血,即按方案内镜治疗后持续出血或成功止血后7天内复发性出血的复合终点。
主要发现
- 按方案止血后持续出血:标准治疗组14例(42.4%),OTSC组2例(6.0%),P=.001。
- 7天内复发性出血:标准治疗组5例(16.1%),OTSC组3例(9.1%),P=.468。
- 进一步出血:标准治疗组19例(57.6%),OTSC组5例(15.2%),绝对差异42.4%(95%CI 21.6-63.2),P=.001。
- 30天随访内需手术治疗:标准治疗组1例(3.0%),OTSC组1例(3.0%),P=.999。
- 30天内死亡:标准治疗组2例(6.3%),OTSC组4例(12.1%),P=.672。
关键数值与推荐
- 标准治疗组持续出血14例(42.4%)vs OTSC组2例(6.0%),P=.001。
- 标准治疗组7天内复发性出血5例(16.1%)vs OTSC组3例(9.1%),P=.468。
- 标准治疗组进一步出血19例(57.6%)vs OTSC组5例(15.2%),绝对差异42.4%(95%CI 21.6-63.2),P=.001。
临床怎么用
- 对于初始止血成功后复发性消化性溃疡出血的成人患者,可考虑使用OTSC进行内镜止血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Endoscopic hemostasis is effective in treatment of bleeding peptic ulcers. However, rebleeding is difficult to treat and associated with substantial morbidity and mortality. We performed a prospective randomized trial to determine whether over-the-scope clips (OTSCs) are more effective than standard treatment of severe recurrent upper gastrointestinal bleeding. METHODS: We performed our study at 9 academic referral centers (in Germany, Switzerland, and Hong Kong) from March 2013 through September 2016. Adult patients with recurrent peptic ulcer bleeding following initially successful hemostasis (66 patients in the intent-to-treat analysis) were randomly assigned to groups (1:1) that underwent hemostasis with either OTSC or standard therapy. Standard therapy was defined as hemostasis with through-the-scope clips (TTSC, n = 31) or thermal therapy plus injection with diluted adrenaline (n = 2). The primary endpoint was further bleeding (a composite endpoint of a persistent bleeding despite endoscopic therapy according to the protocol or recurrent bleeding within 7 days after successful hemostasis). Patients with further bleeding were allowed to cross over to OTSC therapy. Main secondary endpoints were mortality, necessity of surgical or angiographic salvage therapy, duration of stay in the hospital or intensive care, number of blood units transfused, and complications associated with endoscopic therapy. RESULTS: Persistent bleeding after per-protocol hemostasis was observed in 14 patients (42.4%) in the standard therapy group and 2 patients (6.0%) in the OTSC group (P = .001). Recurrent bleeding within 7 days occurred in 5 patients (16.1%) in the standard therapy group vs 3 patients (9.1%) in the OTSC group (P = .468). Further bleeding occurred in 19 patients (57.6%) in the standard therapy group and in 5 patients (15.2%) in the OTSC group (absolute difference 42.4%; 95% confidence interval 21.6-63.2; P = .001) Within 30 days of follow-up, 1 patient in the standard therapy group (3.0%) and 1 patient in the OTSC group (3.0%) required surgical therapy (P = .999). Within 30 days of the procedure, 2 patients died in the standard therapy group (6.3%) and 4 patients died in the OTSC group (12.1%) (P = .672). There were no significant differences in the other secondary endpoints. CONCLUSIONS: In prospective randomized trial, we found endoscopic treatment with OTSCs to be superior to standard therapy with TTSCs for patients with recurrent peptic ulcer bleeding. STING Study, Clinicaltrials.gov no: NCT1836900.
引用
- Schmidt A, Gölder S, Goetz M, et al. Over-the-Scope Clips Are More Effective Than Standard Endoscopic Therapy for Patients With Recurrent Bleeding of Peptic Ulcers. Gastroenterology. 2018. PMID: 29803838. doi:10.1053/j.gastro.2018.05.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。